ReviewBioactive materials2025
Nanotechnology approaches to drug delivery for the treatment of ischemic stroke.
Review in Bioactive materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Review the role of oxygen-delivering nanobubbles in stroke therapy: A novel approach.F1000Research · 2025Pooled it
- Emerging trends and research hotspots of non-invasive brain stimulation for stroke: a bibliometric and visualization study.Frontiers in neurology · 2025Pooled it
- Beyond Recanalization: Neurovascular Unit Protection and Precision Adjunctive Therapy for Ischemic Stroke in the Reperfusion Era.Biomolecules · 2026Review
- Lipid metabolism, microglia, and stroke.Neural regeneration research · 2026Article
- Dual-Responsive Dynamic Covalent Bond-Based Assembly of Lipid-Nanozyme Systems via Multi-Target Synergy and Efficient Target Enrichment for Ischemic Stroke Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Review
- Biomaterials Promote the Regression of Atherosclerotic Plaque by Regulating Cell Behavior.International journal of nanomedicine · 2026Review
- A novel Microtus fortis MCAO model for ischemic stroke: surgical validation and transcriptomic insights.American journal of translational research · 2026Article
- Biomimetic dynamic nanomedicine SrHCF: Lattice self-reconstruction based on FeBioactive materials · 2026Article
- Back Again to the Future: A New Era for Cerebroprotection.Annals of neurology · 2026Review
- Doping-Engineered Proangiogenic Nanozymes Orchestrate Ischemic Tissue Regeneration via Cytoprotection and Revascularization.Research (Washington, D.C.) · 2026Article
- Platelet membrane biomimetic nanoparticle-based targeted delivery system of simvastatin for the treatment of ischemic stroke.PloS one · 2026Article
- Efficient synthesis of tetrazolesRSC advances · 2025Article
- Enhanced Osteogenic Differentiation of hMSCs Using BMP@ZIF-8-Loaded GelMA Nanocomposite Hydrogels with Controlled BMP-2 Release.ACS omega · 2025Article
- Emerging Targeted Delivery Strategies of Nanosystems for Ischemic Stroke Treatment.International journal of nanomedicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Ischemic stroke is a major global public health concern that lacks effective treatment options. A significant challenge lies in delivering therapeutic agents to the brain due to the restrictive nature of the blood-brain barrier (BBB). The BBB's selectivity hampers the delivery of therapeutically relevant quantities of agents to the brain, resulting in a lack of FDA-approved pharmacotherapies for stroke. In this article, we review therapeutic agents that have been evaluated in clinical trials or are currently undergoing clinical trials. Subsequently, we survey strategies for synthesizing and engineering nanoparticles (NPs) for drug delivery to the ischemic brain. We then provide insights into the potential clinical translation of nanomedicine, offering a perspective on its transformative role in advancing stroke treatment strategies. In summary, existing literature suggests that drug delivery represents a major barrier for clinical translation of stroke pharmacotherapies. While nanotechnology has shown significant promise in addressing this challenge, further advancements aimed at improving delivery efficiency and simplifying formulations are necessary for successful clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.